{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T23:21:51Z","timestamp":1720221711675},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2007,9]]},"DOI":"10.1016\/j.vaccine.2007.04.043","type":"journal-article","created":{"date-parts":[[2007,5,8]],"date-time":"2007-05-08T09:33:55Z","timestamp":1178616835000},"page":"A63-A68","source":"Crossref","is-referenced-by-count":4,"special_numbering":"S1","title":["Issues surrounding standardization of meningococcal group W135 serology"],"prefix":"10.1016","volume":"25","author":[{"given":"Paul","family":"Balmer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ray","family":"Borrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2007.04.043_bib1","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJM197002192820803","article-title":"Prevention of meningococcal disease by group C polysaccharide vaccine","volume":"282","author":"Artenstein","year":"1970","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2007.04.043_bib2","first-page":"279","article-title":"Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969\u201370","volume":"45","author":"Gold","year":"1971","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2007.04.043_bib3","first-page":"667","article-title":"A controlled field trial of a serogroup A meningococcal polysaccharide vaccine","volume":"48","author":"Wahdan","year":"1973","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2007.04.043_bib4","first-page":"301","article-title":"A serogroup A meningococcal polysaccharide vaccine: studies in the Sudan to combat cerebrospinal meningitis caused by Neisseria meningitidis group A","volume":"49","author":"Erwa","year":"1973","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2007.04.043_bib5","unstructured":"World Health Organisation. Requirements for meningococcal polysaccharide vaccine. World Health Organization technical report series, no. 594. World Health Organization, Geneva, Switzerland, 1976."},{"key":"10.1016\/j.vaccine.2007.04.043_bib6","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus: I. The role of humoral antibodies","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2007.04.043_bib7","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1084\/jem.129.6.1327","article-title":"Human immunity to the meningococcus: II. Development of natural immunity","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2007.04.043_bib8","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1086\/314753","article-title":"Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory","volume":"179","author":"Richmond","year":"1999","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2007.04.043_bib9","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1128\/IAI.69.4.2378-2382.2001","article-title":"Evaluation of de-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming and bactericidal activity against O-acetylated and de-O-acetylated serogroup C strains","volume":"69","author":"Richmond","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2007.04.043_bib10","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1001\/jama.283.21.2795","article-title":"Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: A randomized controlled trial","volume":"283","author":"MacLennan","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2007.04.043_bib11","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1086\/317646","article-title":"Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers","volume":"183","author":"Richmond","year":"2001","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2007.04.043_bib12","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1128\/JCM.32.6.1475-1482.1994","article-title":"Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay","volume":"32","author":"Gheesling","year":"1994","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2007.04.043_bib13","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/CDLI.4.2.156-167.1997","article-title":"Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays","volume":"4","author":"Maslanka","year":"1997","journal-title":"Clin Diag Lab Immunol"},{"key":"10.1016\/j.vaccine.2007.04.043_bib14","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1006\/biol.2002.0341","article-title":"Assay parameters and methods of data analysis for the comparison of complement sources in the Neisseria meningitidis serogroup C serum bactericidal assay","volume":"30","author":"Jodar","year":"2002","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2007.04.043_bib15","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1128\/JCM.30.1.154-159.1992","article-title":"Multicenter comparison of levels of antibody to the Neisseria meningitidis group A capsular polysaccharide measured by using an enzyme-linked immunosorbent assay","volume":"30","author":"Carlone","year":"1992","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2007.04.043_bib16","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1016\/j.vaccine.2005.01.070","article-title":"Validation of the serum bactericidal assay for measurement of functional antibodies against group B meningococci associated with vaccine trials","volume":"23","author":"Martin","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2007.04.043_bib17","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1128\/CDLI.12.8.970-976.2005","article-title":"Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup B, strain 44\/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine","volume":"12","author":"Borrow","year":"2005","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2007.04.043_bib18","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1128\/IAI.34.3.725-732.1981","article-title":"Safety and immunogenicity of group Y and group W135 meningococcal capsular polysaccharide vaccines in adults","volume":"34","author":"Griffiss","year":"1981","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2007.04.043_bib19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1128\/IAI.37.1.205-208.1982","article-title":"Human immune response to various doses of group Y and W135 meningococcal polysaccharide vaccines","volume":"37","author":"Griffiss","year":"1982","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2007.04.043_bib20","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3181\/00379727-169-41306","article-title":"Clinical and serological evaluation of a meningococcal polysaccharide vaccine groups A, C, Y, and W135","volume":"169","author":"Hankins","year":"1982","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.vaccine.2007.04.043_bib21","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1128\/IAI.42.2.599-604.1983","article-title":"Reactivity and immunogenicity of bivalent (AC) and tetravalent (ACW135Y) meningococcal vaccines containing O-acetyl-negative or O-acetyl-positive group C polysaccharide","volume":"42","author":"Vodopija","year":"1983","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2007.04.043_bib22","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0092-1157(82)80010-3","article-title":"Tetravalent meningococcal polysaccharide vaccine groups A, C, Y, W 135: clinical and serological evaluation","volume":"10","author":"Armand","year":"1982","journal-title":"J Biol Stand"},{"key":"10.1016\/j.vaccine.2007.04.043_bib23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1542\/peds.76.1.91","article-title":"Evaluation of two tetravalent (ACYW135) meningococcal vaccines in infants and small children: a clinical study comparing immunogenicity of O-acetyl-negative and O-acetyl-positive group C polysaccharides","volume":"76","author":"Peltola","year":"1985","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2007.04.043_bib24","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1128\/IAI.73.5.2932-2939.2005","article-title":"Immunogenicity of a meningococcal ACYW135 polysaccharide vaccine in Saudi children aged under 5 years","volume":"73","author":"Al-Mazrou","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2007.04.043_bib25","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1172\/JCI108235","article-title":"Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants","volume":"56","author":"Gold","year":"1975","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2007.04.043_bib26","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1086\/345763","article-title":"Safety, reactogenicity, and immunogenicity of a tetravalent meningococcal polysaccharide-diphtheria toxoid conjugate vaccine given to healthy adults","volume":"186","author":"Campbell","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2007.04.043_bib27","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1097\/00006454-200210000-00019","article-title":"Dose escalation, safety and immunogenicity study of a tetravalent meninogococcal polysaccharide diphtheria conjugate vaccine in toddlers","volume":"21","author":"Rennels","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2007.04.043_bib28","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/01.inf.0000126297.28952.f8","article-title":"Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants","volume":"23","author":"Rennels","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2007.04.043_bib29","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/archpedi.159.10.907","article-title":"Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents","volume":"159","author":"Keyserling","year":"2005","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1016\/j.vaccine.2007.04.043_bib30","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/01.inf.0000148928.10057.86","article-title":"Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children","volume":"24","author":"Pichichero","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2007.04.043_bib31","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.1016\/j.vaccine.2005.03.031","article-title":"Immunogenicity of an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine in 2-year old children","volume":"23","author":"Granoff","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2007.04.043_bib32","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1016\/j.vaccine.2005.12.018","article-title":"Antibody responses to meningococcal (groups A, C, Y and W135) polysaccharide diphtheria toxoid conjugate vaccine in children who previously received meningococcal C conjugate vaccine","volume":"24","author":"Bashir","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2007.04.043_bib33","unstructured":"FDA Statistical Review and Evaluation. Document for the Vaccines and Related Biological Products Advisory Committee (VRBPAC), September 22nd 2004. Menactra, Meningococcal (Groups A, C, Y, and W135) polysaccharide diphtheria toxoid conjugate vaccine. Available at http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/04\/briefing\/4072B1_2b.htm. Accessed 26 January 2006."},{"key":"10.1016\/j.vaccine.2007.04.043_bib34","unstructured":"World Health Organisation. Requirements for meningococcal polysaccharide vaccine. World Health Organization technical report series, no. 23. World Health Organization, Geneva, Switzerland. 1980."},{"key":"10.1016\/j.vaccine.2007.04.043_bib35","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1086\/499822","article-title":"Predictors of immunity after a major serogroup W-135 meningococcal disease epidemic, Burkino Faso, 2002","volume":"193","author":"Raghunathan","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2007.04.043_bib36","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1128\/CDLI.12.10.1251-1253.2005","article-title":"Immunogenicity of meningococcal ACYW135 polysaccharide vaccine in Saudi Children aged 5 to 9 years","volume":"12","author":"Khalil","year":"2005","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2007.04.043_bib37","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1128\/CVI.13.4.507-510.2006","article-title":"IgG subclass response to a meningococcal tetravalent polysaccharide-diphtheria toxoid conjugate vaccine","volume":"13","author":"Findlow","year":"2006","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2007.04.043_bib38","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1086\/500511","article-title":"Neisseria meningitidis serogroups A and W-135: Carriage and Immunity in Burkina Faso","volume":"193","author":"Mueller","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2007.04.043_bib39","doi-asserted-by":"crossref","unstructured":"Boisier P, Nicolas P, Djibo S, Amadou Hamidou A, Sidikou F, Chanteau S. Self-contained outburst of meningitis due to Neisseria meningitidis serogroup W135, ST-2881, in Niger with high rates of asymptomatic carriage in the community. Presented at Medicine and Health in the Tropics. Marseille, France, 11\u201315 September 2005, Abstract n\u00b0 P591.","DOI":"10.3201\/eid1209.051518"},{"key":"10.1016\/j.vaccine.2007.04.043_bib40","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1046\/j.1365-2958.2003.03819.x","article-title":"Genetics of capsule O-acetylation in serogroup C, W-135, and Y meningococci","volume":"51","author":"Claus","year":"2004","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.vaccine.2007.04.043_bib41","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1574-695X.2002.tb00543.x","article-title":"O-Acetylation status of the capsular polysaccharides of serogroup Y and W135 meningococci in the UK","volume":"32","author":"Longworth","year":"2002","journal-title":"FEMS Immunol Med Microbiol"},{"key":"10.1016\/j.vaccine.2007.04.043_bib42","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1128\/IAI.70.7.3707-3713.2002","article-title":"Effect of O acetylation of Neisseria meningitidis serogroup A capsular polysaccharide on development of functional immune responses","volume":"70","author":"Berry","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2007.04.043_bib43","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1128\/CDLI.12.5.586-592.2005","article-title":"analysis of human serum immunoglobulin G against O-acetyl-positive and O-acetyl-negative serogroup W135 meningococcal capsular polysaccharide","volume":"12","author":"Giardina","year":"2005","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2007.04.043_bib44","series-title":"Handbook of Meningococcal Disease","first-page":"323","article-title":"Surrogates of protection","author":"Borrow","year":"2006"},{"key":"10.1016\/j.vaccine.2007.04.043_bib45","unstructured":"CBER Introduction to licensure application: Aventis Pasteur licensure application for Meningococcal (groups A, C, Y, and W135) polysaccharide diphtheria toxoid conjugate vaccine. Available at: http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/04\/slides\/4072S1_1.ppt. Accessed 26 January 2006."},{"key":"10.1016\/j.vaccine.2007.04.043_bib46","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/01.inf.0000151035.64356.f8","article-title":"Persistence of group C anticapsular antibodies two to three years after immunization with an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine","volume":"24","author":"Granoff","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2007.04.043_bib47","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1128\/IAI.69.3.1568-1573.2001","article-title":"Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: a re-evaluation of correlates of protection","volume":"69","author":"Borrow","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2007.04.043_bib48","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1128\/CDLI.10.5.780-786.2003","article-title":"Validation of serological correlate of protection for meningococcal C conjugate vaccine using efficacy estimates from post-licensure surveillance in England","volume":"10","author":"Andrews","year":"2003","journal-title":"Clin Diag Lab Immunol"},{"key":"10.1016\/j.vaccine.2007.04.043_bib49","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1128\/CDLI.2.2.132-137.1995","article-title":"Assignement of Neisseria meningitidis serogroup A and C class-specific anticapsular antibody concentrations to the new standard reference serum CDC","volume":"2","author":"Holder","year":"1995","journal-title":"Clin Diag Lab Immunol"},{"key":"10.1016\/j.vaccine.2007.04.043_bib50","first-page":"725","article-title":"Assignment of additional anticapsular antibody concentrations to the Neisseria meningitidis group A, C, Y and W-135 meningococcal standard reference serum CDC","volume":"9","author":"Elie","year":"2002","journal-title":"Clin Diag Lab Immun"},{"key":"10.1016\/j.vaccine.2007.04.043_bib51","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1128\/CDLI.11.2.272-279.2004","article-title":"Development and evaluation of a multiplex flow cytometric assay for quantitation of serum antibodies to Neisseria meningitidis serogroups A, C, Y and W-135","volume":"11","author":"Lal","year":"2004","journal-title":"Clin Diag Lab Immunol"},{"key":"10.1016\/j.vaccine.2007.04.043_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CDLI.11.1.1-5.2004","article-title":"Assignment of Neisseria meningitidis serogroups A, C, W135 and Y anticapsular immunoglobulin G (IgG), IgG1 and IgG2 concentrations to reference sera","volume":"11","author":"Joseph","year":"2004","journal-title":"J Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2007.04.043_bib53","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1056\/NEJM197709292971302","article-title":"Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age","volume":"297","author":"Peltola","year":"1977","journal-title":"N Engl J Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X07004689?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X07004689?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T15:02:40Z","timestamp":1683817360000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X07004689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":53,"alternative-id":["S0264410X07004689"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2007.04.043","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2007,9]]}}}